Business Context and Reporting Period
This Form 8-K is filed by NAYA Biosciences, Inc. (not INVO Fertility, Inc.) on March 7, 2025. The filing addresses the postponement of the company's 2024 Annual Meeting of Stockholders (ASM) and efforts to regain compliance with Nasdaq listing rules regarding the timing of annual meetings.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses the following specific financial obligation:
- Debt: An outstanding 7.0% Senior Secured Convertible Debenture with a principal balance of $3,934,146, due December 11, 2025.
- Liquidity/Capital Structure: The company is seeking stockholder approval to increase authorized common stock from 50,000,000 to 100,000,000 shares (post-reverse split) and to increase shares available under its Stock Incentive Plan to 8,200,000 (pre-reverse split).
Material Changes and Events
- Meeting Postponement: The 2024 ASM, originally scheduled for March 10, 2025, has been postponed to April 9, 2025.
- Vote Nullification: All votes cast in the February 2025 proxy statement are null and void due to the new record date of March 10, 2025. Stockholders must vote again on a new proxy statement.
- Proposal Status: While "Standard Proposals" (director election and auditor ratification) received sufficient votes initially, several "Special Proposals" (including stock issuance for debt conversion and plan amendments) did not garner necessary votes.
- Board Composition Change: The new proxy will propose the re-election of existing directors, replacing the "New Board Slate" proposed in the February filing.
Outlook, Risks, and Management Commentary
- Nasdaq Compliance: The company is working to regain compliance with Nasdaq Rules 5620(a) and 5801(s)(2)(G), which require an annual meeting within 12 months of the fiscal year-end.
- Extension Granted: Nasdaq staff granted an extension until June 30, 2025, for the company to regain compliance with the annual meeting rule.
- Strategic Separation: The company plans to address the "Special Proposals" (capital structure changes) separately from the "Standard Proposals" in future filings.
- Reverse Stock Split: The board has authority to implement a reverse stock split ranging from 1-for-2 to 1-for-20, though this remains subject to board discretion and may be abandoned.
Investor Verification Checklist
- Verify the new record date of March 10, 2025, for eligibility to vote at the rescheduled April 9, 2025 meeting.
- Confirm the status of the $3.93 million convertible debenture due in December 2025 and the likelihood of its conversion given the failed special proposals.
- Monitor the upcoming "March Proxy" for the revised list of director nominees and the specific timeline for the separate special proposals.
- Check for any further Nasdaq communications regarding the June 30, 2025 compliance deadline.